May 17, 2021
Authored and Edited by Adriana L. Burgy; Daniele M. San Román; Kyu Yun Kim; Thomas L. Irving; Stacy Lewis*
In the U.S., a prosecution history of a patent (i.e., the proceedings between the patent applicant and the USPTO from application filing to patent issuance) comes into play in the context of claim construction (for example, before a district court, before the PTAB in a post-grant proceeding, or in the eyes of a third party analyzing the patent for freedom to operate reasons), and also in the context of an assessment of infringement under the doctrine of equivalents.
But the line between the two uses of a patent’s prosecution history tends to be blurry. In Part 1 of this series, https://www.finnegan.com/en/insights/blogs/prosecution-first/part-1-prosecution-history-in-claim-interpretation.html, we looked at the use of prosecution history in claim construction. Here in Part 2, we discuss its use in a doctrine of equivalents analysis.
A prosecution history may limit a range of infringement available under the doctrine of equivalents. Prosecution history estoppel prevents a patentee from using the doctrine of equivalents to recapture subject matter surrendered during prosecution from the literal scope of a claim. See Hoganas AB v. Dresser Indus., Inc., 9 F.3d 948, 950 at n.6 (Fed. Cir. 1993).
Prosecution history estoppel can arise from a variety of acts taken during prosecution. For example, it is well settled that amendments made in response to prior art rejections can result in prosecution history estoppel. This is frequently called “classical” prosecution history estoppel. Hughes Aircraft Co. v. U.S., 717 F.2d 1351, 1362 (Fed. Cir. 1983); Keystone Driller Co. v. Northwest Eng'g Corp., 294 U.S. 42, 48 (1935). An applicant cannot amend the claims in response to an examiner's rejection and then use the doctrine of equivalents to try to obtain the very same subject matter that was given up to obtain the patent. See Hilgraeve Corp. v. McAfee Assoc., Inc., 224 F.3d 1349 (Fed. Cir. 2000); Sextant Avionique, S.A. v. Analog Devices, Inc., 172 F.3d 817, 819 (Fed. Cir. 1999); Loral Fairchild Corp. v. Sony Corp., 181 F.3d 1313 (Fed. Cir. 1999); Chemical Eng'g Corp. v. Essef Indus., Inc., 795 F.2d 1565 (Fed. Cir. 1986).
Estoppel may also be created by arguments and representations made to the USPTO to obtain allowance of a patent, even without a claim amendment. Andersen Corp. v. Fiber Composites LLC, 474 F.3d 1361 (Fed. Cir. 2007). This is where the line becoming blurry with claim construction is most noticeable. Unmistakable assertions to the USPTO in support of patentability, whether or not they were required to secure allowance of the claims, will estop the patentee from obtaining protection of the subject matter surrendered via the doctrine of equivalents. Athletic Alternatives, Inc. v. Prince Mfg., Inc., 73 F.3d 1573, 1582 (Fed. Cir. 1996) (citing Kinzenbaw v. Deere & Co., 741 F.2d 383, 389 (Fed. Cir. 1984)); see also, Amgen Inc. v. Coherus BioSciences, Inc., 931 F.3d 1154 (Fed. Cir. 2019) (Amgen “clearly and unmistakably—and indeed, repeatedly—indicated to competitors that it surrendered processes using combinations of salts different from the 'particular combinations of salts recited in the . . . claims[.]’”); Pharma Tech Sols., Inc. v. LifeScan, Inc., 942 F.3d 1372, 1380 (Fed. Cir. 2019); Abbott Lab’ies. v. Dey, 287 F.3d 1097 (Fed. Cir. 2002); Pharmacia & Upjohn Co. v. Mylan Pharms., Inc., 170 F.3d 1373 (Fed. Cir. 1999); Bai v. L&L Wings, Inc., 160 F.3d 1350, 1356 (Fed. Cir. 1998); Insituform Techs., Inc. v. CAT Contracting, Inc., 99 F.3d 1098, 1108-09 (Fed. Cir. 1996).
The Federal Circuit stated that representations made to foreign patent offices may also be considered in determining the applicability of prosecution history estoppel. “[R]epresentations to foreign patent offices should be considered . . . when [they] comprise relevant evidence.” Caterpillar Tractor Co. v. Berco, S.p.A., 714 F.2d 1110, 1116 (Fed. Cir. 1983). A court will consider statements made in foreign prosecution when:
The statement was made in an official proceeding where the patentee had every incentive to exercise care in characterizing the scope of its invention;
The patents are related and/or share an identical claim; and the statement was not related to unique aspects of foreign patent law.
Apple Inc. v. Motorola, Inc., 757 F.3d 1286, 1312 (Fed. Cir. 2014). See also Tanabe Seiyaku Co., Ltd. v. USITC, 109 F.3d 726 (Fed. Cir. 1997); Merck & Co., Inc. v. Mylan Pharms., Inc., 19 F.Supp.2d 334 (E.D. Penn. 1998).
Prosecution history estoppel resulting from arguments and amendments regarding one claim may be applied to limit the scope of other claims not only in the same patent but also in related patents. Southwall Techs., Inc. v. Cardinal IG Co., 54 F.3d 1570 (Fed. Cir. 1995); Diversitech Corp. v. Century Steps, Inc., 850 F.2d 675 (Fed. Cir. 1988); Builders Concrete, Inc. v. Bremerton Concrete Prods. Co., 757 F.2d 255 (Fed. Cir. 1985). Prosecution history estoppel, however, may not apply to patents issued before the acts that gave rise to the estoppel. See Water Tech. Corp. v. Calco, Ltd., 850 F.2d 660, 667 (Fed. Cir. 1988).
Consider the following suggestions to avoid creating prosecution history that may lead to estoppel in a doctrine of equivalents analysis.
prosecution history estoppel, Doctrine of Equivalents, United States Patent and Trademark Office (USPTO)
*Stacy Lewis is a Law Clerk at Finnegan.
Copyright © 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
June 10-12, 2024
San Francisco
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.